Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • For authors
    • Instructions for authors
    • Submit a manuscript
    • Author FAQs
    • Open access
    • COVID-19 submission information
  • Alerts
  • Podcasts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • For authors
    • Instructions for authors
    • Submit a manuscript
    • Author FAQs
    • Open access
    • COVID-19 submission information
  • Alerts
  • Podcasts
  • Subscriptions

Progressive fibrosing interstitial lung disease: a clinical cohort (the PROGRESS study)

Mouhamad Nasser, Sophie Larrieu, Salim Si-Mohamed, Kaïs Ahmad, Loic Boussel, Marie Brevet, Lara Chalabreysse, Céline Fabre, Sébastien Marque, Didier Revel, Françoise Thivolet-Bejui, Julie Traclet, Sabrina Zeghmar, Delphine Maucort-Boulch, Vincent Cottin
European Respiratory Journal 2021 57: 2002718; DOI: 10.1183/13993003.02718-2020
Mouhamad Nasser
1Dept of Respiratory Medicine, National Coordinating Reference Centre for Rare Pulmonary Diseases, OrphaLung, Louis Pradel Hospital, University Hospital of Lyon, Lyon, France
2Claude Bernard University Lyon 1, UMR754 INRAE, IVPC, Lyon, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Mouhamad Nasser
Sophie Larrieu
3IQVIA, La Défense, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Sophie Larrieu
Salim Si-Mohamed
4Dept of Radiology, University Hospital of Lyon, Lyon, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Salim Si-Mohamed
Kaïs Ahmad
1Dept of Respiratory Medicine, National Coordinating Reference Centre for Rare Pulmonary Diseases, OrphaLung, Louis Pradel Hospital, University Hospital of Lyon, Lyon, France
2Claude Bernard University Lyon 1, UMR754 INRAE, IVPC, Lyon, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Loic Boussel
4Dept of Radiology, University Hospital of Lyon, Lyon, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marie Brevet
5Dept of Pathology, University Hospital of Lyon, Lyon, France
6CYPATH, Villeurbanne, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lara Chalabreysse
5Dept of Pathology, University Hospital of Lyon, Lyon, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Céline Fabre
3IQVIA, La Défense, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sébastien Marque
3IQVIA, La Défense, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Didier Revel
4Dept of Radiology, University Hospital of Lyon, Lyon, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Françoise Thivolet-Bejui
5Dept of Pathology, University Hospital of Lyon, Lyon, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Julie Traclet
1Dept of Respiratory Medicine, National Coordinating Reference Centre for Rare Pulmonary Diseases, OrphaLung, Louis Pradel Hospital, University Hospital of Lyon, Lyon, France
2Claude Bernard University Lyon 1, UMR754 INRAE, IVPC, Lyon, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sabrina Zeghmar
1Dept of Respiratory Medicine, National Coordinating Reference Centre for Rare Pulmonary Diseases, OrphaLung, Louis Pradel Hospital, University Hospital of Lyon, Lyon, France
2Claude Bernard University Lyon 1, UMR754 INRAE, IVPC, Lyon, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Delphine Maucort-Boulch
7Dept of Biostatistics, University Hospital of Lyon, Lyon, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Delphine Maucort-Boulch
Vincent Cottin
1Dept of Respiratory Medicine, National Coordinating Reference Centre for Rare Pulmonary Diseases, OrphaLung, Louis Pradel Hospital, University Hospital of Lyon, Lyon, France
2Claude Bernard University Lyon 1, UMR754 INRAE, IVPC, Lyon, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Vincent Cottin
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

In patients with chronic fibrosing interstitial lung disease (ILD), a progressive fibrosing phenotype (PF-ILD) may develop, but information on the frequency and characteristics of this population outside clinical trials is lacking.

We assessed the characteristics and outcomes of patients with PF-ILD other than idiopathic pulmonary fibrosis (IPF) in a real-world, single-centre clinical cohort. The files of all consecutive adult patients with fibrosing ILD (2010–2017) were examined retrospectively for pre-defined criteria of ≥10% fibrosis on high-resolution computed tomography and progressive disease during overlapping windows of 2 years. Baseline was defined as the date disease progression was identified. Patients receiving nintedanib or pirfenidone were censored from survival and progression analyses.

In total, 1395 patients were screened; 617 had ILD other than IPF or combined pulmonary fibrosis and emphysema, and 168 had progressive fibrosing phenotypes. In 165 evaluable patients, median age was 61 years; 57% were female. Baseline mean forced vital capacity (FVC) was 74±22% predicted. Median duration of follow-up was 46.2 months. Annualised FVC decline during the first year was estimated at 136±328 mL using a linear mixed model. Overall survival was 83% at 3 years and 72% at 5 years. Using multivariate Cox regression analysis, mortality was significantly associated with relative FVC decline ≥10% in the previous 24 months (p<0.05), age ≥50 years (p<0.01) and diagnosis subgroup (p<0.01).

In this cohort of patients with PF-ILD not receiving antifibrotic therapy, the disease followed a course characterised by continued decline in lung function, which predicted mortality.

Abstract

In a real-world clinical cohort (PROGRESS), progressive fibrosing interstitial lung disease was characterised by continued lung function decline. Lung function decline, age and underlying diagnosis subgroup predicted mortality. https://bit.ly/2EB3OpF

Footnotes

  • This article has supplementary material available from erj.ersjournals.com

  • This study is registered with ClinicalTrials.gov number NCT03858842.

  • Conflict of interest: M. Nasser received sponsorship for conference attendance from Boehringer Ingelheim and Hoffmann-La Roche, and received consultation fees from Boehringer Ingelheim.

  • Conflict of interest: S. Larrieu has nothing to disclose.

  • Conflict of interest: S. Si-Mohamed has nothing to disclose.

  • Conflict of interest: K. Ahmad reports relationships and activities from Roche and Boehringer Ingelheim, outside the submitted work.

  • Conflict of interest: L. Boussel has nothing to disclose.

  • Conflict of interest: M. Brevet has nothing to disclose.

  • Conflict of interest: L. Chalabreysse has nothing to disclose.

  • Conflict of interest: C. Fabre has nothing to disclose.

  • Conflict of interest: S. Marque has nothing to disclose.

  • Conflict of interest: D. Revel declares provision of scientific expertise under contract with IQVIA.

  • Conflict of interest: F. Thivolet-Bejui has nothing to disclose.

  • Conflict of interest: J. Traclet reports sponsorship for meeting attendance from Roche and Boehringer Ingelheim, outside the submitted work.

  • Conflict of interest: S. Zeghmar has nothing to disclose.

  • Conflict of interest: D. Maucort-Boulch has nothing to disclose.

  • Conflict of interest: V. Cottin reports personal fees for advisory board work and lectures, and non-financial support for meeting attendance from Actelion, grants, personal fees for consultancy and lectures, and non-financial support for meeting attendance from Boehringer Ingelheim and Roche, personal fees for advisory board and data monitoring committee work from Bayer/MSD, personal fees for advisory board work and lectures from Novartis, personal fees for lectures from Sanofi, personal fees for data monitoring and steering committee work from Promedior, personal fees for data monitoring committee work from Celgene and Galecto, and personal fees for advisory board and data monitoring committee work from Galapagos, outside the submitted work.

  • Support statement: The PROGRESS trial was funded by an unrestricted grant from Boehringer Ingelheim International GmbH (BI) to Hospices Civils de Lyon. IQVIA received financial support from Boehringer Ingelheim Santé Humaine France for the design, monitoring, data-management and statistical analysis of the study. Medical writing, editorial support and formatting assistance were provided by Helen Keyworth of Nucleus Global, which was contracted and funded by BI. The authors did not receive payment for the development of the manuscript. Funding information for this article has been deposited with the Crossref Funder Registry.

  • Received March 18, 2020.
  • Accepted August 24, 2020.
  • Copyright ©ERS 2021
https://www.ersjournals.com/user-licence
View Full Text

ERS Members

myERS - ERS members : log in with your myERS username and password.

INDIVIDUALS

Log in Login as an individual user.

Forgot your username or password?

LIBRARY USERS

Log in through your institution

If your library has a subscription, you may already be logged in via your IP address. Otherwise you may be able to log in via one of the following routes.
You may be able to gain access using your login credentials for your institution. Contact your library if you do not have a username and password.
If your organization uses OpenAthens, you can log in using your OpenAthens username and password. To check if your institution is supported, please see this list. Contact your library for more details.
If you think you should have access, please contact your librarian or email journals@ersnet.org

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top
View this article with LENS
Vol 57 Issue 2 Table of Contents
European Respiratory Journal: 57 (2)
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Progressive fibrosing interstitial lung disease: a clinical cohort (the PROGRESS study)
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Alerts
Sign In to Email Alerts with your Email Address
Citation Tools
Progressive fibrosing interstitial lung disease: a clinical cohort (the PROGRESS study)
Mouhamad Nasser, Sophie Larrieu, Salim Si-Mohamed, Kaïs Ahmad, Loic Boussel, Marie Brevet, Lara Chalabreysse, Céline Fabre, Sébastien Marque, Didier Revel, Françoise Thivolet-Bejui, Julie Traclet, Sabrina Zeghmar, Delphine Maucort-Boulch, Vincent Cottin
European Respiratory Journal Feb 2021, 57 (2) 2002718; DOI: 10.1183/13993003.02718-2020

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Progressive fibrosing interstitial lung disease: a clinical cohort (the PROGRESS study)
Mouhamad Nasser, Sophie Larrieu, Salim Si-Mohamed, Kaïs Ahmad, Loic Boussel, Marie Brevet, Lara Chalabreysse, Céline Fabre, Sébastien Marque, Didier Revel, Françoise Thivolet-Bejui, Julie Traclet, Sabrina Zeghmar, Delphine Maucort-Boulch, Vincent Cottin
European Respiratory Journal Feb 2021, 57 (2) 2002718; DOI: 10.1183/13993003.02718-2020
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Abstract
    • Abstract
    • Introduction
    • Materials and methods
    • Results
    • Discussion
    • Supplementary material
    • Shareable PDF
    • Acknowledgements
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Subjects

  • Interstitial and orphan lung disease
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

Original Articles

  • Chronic bronchitis and risk factors in young adults
  • Asthma medication and prognosis of patients with COVID-19
  • Asthma medication in obese and healthy weight asthma
Show more Original Articles

Interstitial lung disease

  • Methotrexate and rheumatoid arthritis-associated ILD
  • Phase 2 trial to assess lebrikizumab in IPF
Show more Interstitial lung disease

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Reviewers
  • CME
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Submit a manuscript
  • ERS author centre

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2021 by the European Respiratory Society